Overview of NRG1 Fusions

Opinion
Video

Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.

Educational support for this activity provided by Merus.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Related Content
Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Tim Cortese
March 26th 2025
Article

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

Tim Cortese
March 12th 2025
Article

The OSE2101 cancer vaccine plus FOLFIRI chemotherapy demonstrated positive survival data with minimal toxicities in the phase 2 TEDOPaM trial.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.

Lower Liposomal Irinotecan/Oxaliplatin Doses Do Not Worsen PDAC Outcomes

Jax DiEugenio
January 25th 2025
Article

Post hoc analysis of the phase 3 NAPOLI 3 trial assessed how dose reductions in liposomal irinotecan/oxaliplatin affect OS in NALIRIFOX-treated PDAC.

Pelareorep Combination Shows Manageable Safety in Metastatic Pancreatic Cancer

Pelareorep Combination Shows Manageable Safety in Metastatic Pancreatic Cancer

Kristi Rosa
January 25th 2025
Article

Cohort 5 of the ongoing phase 1/2 GOBLET study evaluated the safety of pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.